(Q36150628)

12 August 2017

1 reference

title

Emerging chemotherapeutic strategies for Huntington's disease (English)

1 reference

12 August 2017

0 references

1 reference

1

Hoon Ryu

1 reference

12 August 2017

2

Robert J Ferrante

1 reference

PubMed ID

15934871

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

1 reference

12 August 2017

10

1 reference

12 August 2017

2

1 reference

12 August 2017

345-363

1 reference

A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

De novo expansion of a (CAG)n repeat in sporadic Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Clinical markers of early disease in persons near onset of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Impact of Huntington's disease on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Selective sparing of a class of striatal neurons in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

The neuropathology of CAG repeat diseases: review and update of genetic and molecular features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

A controlled trial of remacemide hydrochloride in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Trial of d-alpha-tocopherol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

A controlled trial of idebenone in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Riluzole therapy in Huntington's disease (HD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Targeting coenzyme Q derivatives to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Experimental therapeutics in transgenic mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Toward understanding the molecular pathology of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Transcriptional dysregulation in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Evidence for a recruitment and sequestration mechanism in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Impairment of the ubiquitin-proteasome system by protein aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Mitochondria as the central control point of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Cross-talk in cell death signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Cytochrome C and caspase-9 expression in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Formation of γ-glutamyl-ε-lysine bridges between membrane proteins by a Ca2+-regulated enzyme in intact erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Cysteamine-induced Increase of Cellular Glutathione-level : A New Hypothesis of the Radioprotective Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Tissue transglutaminase triggers oligomerization and activation of dual leucine zipper-bearing kinase in calphostin C-treated cells to facilitate apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Selective depletion of somatostatin in rat brain by cysteamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Apoptosis and caspases in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Minocycline in phenotypic models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

In vivo studies on the protective role of minocycline against excitotoxicity caused by malonate or N-methyl-d-aspartate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Minocycline safety and tolerability in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Minocycline in Huntington's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Neuroprotection in Huntington's disease: a 2-year study on minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Maintained improvement with minocycline of a patient with advanced Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Clinical potential of minocycline for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

The promise of minocycline in neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Antibacterial therapy for acne: a guide to selection and use of systemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Linking the epigenetic 'language' of covalent histone modifications to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: roles of minor groove width and ligand flexibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Analysis of two chromosomal regions adjacent to genes for a type II polyketide synthase involved in the biosynthesis of the antitumor polyketide mithramycin in Streptomyces argillaceus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Interaction of Huntington disease protein with transcriptional activator Sp1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Binding and catalytic properties of the Cdc2 and Crp proteins of Dictyostelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Treatment of spinal muscular atrophy by sodium butyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Sodium butyrate inhibits histone deacetylation in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Alternative pathway therapy for urea cycle disorders: twenty years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Mitochondrial defect in Huntington's disease caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Transport of energy in muscle: the phosphorylcreatine shuttle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Creatine supplementation lowers brain glutamate levels in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Direct antioxidant properties of creatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Superoxide activates mitochondrial uncoupling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Mitochondrial ROS metabolism: modulation by uncoupling proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Choreic movements and MRI abnormalities in the subthalamic nuclei reversible after administration of coenzyme Q10 and multiple vitamins in a patient with bilateral optic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Effects of coenzyme Q10 and alpha-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial alpha-tocopherol by coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Familial cerebellar ataxia with muscle coenzyme Q10 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.345

10.1517/14728214.10.2.345

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15934871